Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 3
2006 3
2007 2
2008 2
2009 3
2010 3
2011 2
2012 2
2013 3
2014 7
2015 4
2016 4
2017 5
2018 8
2019 9
2020 22
2021 28
2022 23
2023 30
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

154 results

Results by year

Filters applied: . Clear all
Page 1
Distribution and clinical impact of molecular subtypes with dark zone signature of DLBCL in a Japanese real-world study.
Urata T, Naoi Y, Jiang A, Boyle M, Sunami K, Imai T, Nawa Y, Hiramatsu Y, Yamamoto K, Fujii S, Yoshida I, Yano T, Chijimatsu R, Murakami H, Ikeuchi K, Kobayashi H, Tani K, Ujiie H, Inoue H, Tomida S, Yamamoto A, Kondo T, Fujiwara H, Asada N, Nishimori H, Fujii K, Fujii N, Matsuoka KI, Sawada K, Momose S, Tamaru JI, Nishikori A, Sato Y, Yoshino T, Maeda Y, Scott DW, Ennishi D. Urata T, et al. Among authors: matsuoka ki. Blood Adv. 2023 Dec 26;7(24):7459-7470. doi: 10.1182/bloodadvances.2023010402. Blood Adv. 2023. PMID: 37552496 Free PMC article.
Cytomegalovirus gastroenteritis in patients with acute graft-versus-host disease.
Akahoshi Y, Kimura SI, Tada Y, Matsukawa T, Tamaki M, Doki N, Uchida N, Tanaka M, Nakamae H, Kuriyama T, Matsuoka KI, Ikeda T, Kimura T, Fukuda T, Kanda Y, Atsuta Y, Murata M, Terakura S, Nakasone H. Akahoshi Y, et al. Among authors: matsuoka ki. Blood Adv. 2022 Jan 25;6(2):574-584. doi: 10.1182/bloodadvances.2021005885. Blood Adv. 2022. PMID: 34788389 Free PMC article.
Novel risk assessment for the intensity of conditioning regimen in older patients.
Akahoshi Y, Tada Y, Sakaida E, Kusuda M, Doki N, Uchida N, Fukuda T, Tanaka M, Sawa M, Katayama Y, Matsuoka KI, Ozawa Y, Onizuka M, Kanda J, Kanda Y, Atsuta Y, Nakasone H. Akahoshi Y, et al. Among authors: matsuoka ki. Blood Adv. 2023 Sep 12;7(17):4738-4747. doi: 10.1182/bloodadvances.2022008706. Blood Adv. 2023. PMID: 36508283 Free PMC article.
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML.
Terao T, Matsuoka KI, Ueda H, Matsumura A, Matsubara C, Kondo K, Kondo T, Fujiwara H, Asada N, Ennishi D, Nishimori H, Fujii K, Fujii N, Maeda Y. Terao T, et al. Among authors: matsuoka ki. Blood Adv. 2023 Mar 14;7(5):681-686. doi: 10.1182/bloodadvances.2022008991. Blood Adv. 2023. PMID: 36583677 Free PMC article. No abstract available.
Hematopoietic stem cell-derived Tregs are essential for maintaining favorable B cell lymphopoiesis following posttransplant cyclophosphamide.
Sumii Y, Kondo T, Ikegawa S, Fukumi T, Iwamoto M, Nishimura MF, Sugiura H, Sando Y, Nakamura M, Meguri Y, Matsushita T, Tanimine N, Kimura M, Asada N, Ennishi D, Maeda Y, Matsuoka KI. Sumii Y, et al. Among authors: matsuoka ki. JCI Insight. 2023 Apr 24;8(8):e162180. doi: 10.1172/jci.insight.162180. JCI Insight. 2023. PMID: 37092551 Free PMC article.
Low- versus standard-dose post-transplant cyclophosphamide as GVHD prophylaxis for haploidentical transplantation.
Fuji S, Sugita J, Najima Y, Konishi T, Tanaka T, Ohigashi H, Eto T, Nagafuji K, Hiramoto N, Matsuoka KI, Maruyama Y, Ota S, Ishikawa J, Kawakita T, Akasaka T, Kamimura T, Hino M, Fukuda T, Atsuta Y, Yakushijin K. Fuji S, et al. Among authors: matsuoka ki. Br J Haematol. 2024 Mar;204(3):959-966. doi: 10.1111/bjh.19228. Epub 2023 Nov 30. Br J Haematol. 2024. PMID: 38037468
154 results